Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics' SEC filings reveal the complex financial and operational realities of clinical-stage gene therapy development. Unlike established pharmaceutical companies with predictable revenue streams, Abeona's regulatory documents tell the story of a company navigating expensive clinical trials, manufacturing scale-up challenges, and the binary outcomes inherent to drug development.
The company's 10-K annual reports and 10-Q quarterly filings detail research and development expenditures across multiple therapeutic programs, providing transparency into how capital is allocated between pipeline candidates targeting epidermolysis bullosa, Sanfilippo syndrome, and other rare genetic conditions. These filings break down clinical trial costs, manufacturing investments, and the cash runway calculations critical for assessing a development-stage biotech's financial sustainability.
Form 4 insider transaction filings track when Abeona executives and directors buy or sell company shares. For clinical-stage biotechnology companies, insider trading patterns sometimes precede material announcements related to clinical data or regulatory decisions. Our AI surfaces these Form 4 filings alongside executive compensation disclosures from proxy statements to provide context on management alignment with shareholders.
Abeona's 8-K filings capture material events including clinical trial milestones, FDA regulatory interactions, partnership agreements, and financing transactions. These current report filings often contain the earliest public disclosure of developments that move the stock. The AI-powered summaries identify key information within these filings, saving you from parsing dense legal language.
Access the complete archive of Abeona Therapeutics SEC documents with AI explanations that translate complex gene therapy accounting, equity compensation structures, and clinical development disclosures into understandable insights.
Abeona Therapeutics (ABEO) Form 144: An insider notice shows a proposed sale of 9,366 shares of common stock to be executed on 09/29/2025 through Stifel Nicolaus. The filing states these shares were acquired as restricted stock units on 09/28/2025 and the aggregate market value of the proposed sale is listed as $50,516.00. The filing also discloses three recent sales by the same person, Joseph Vazzano, totaling 41,913 shares sold on 07/09/2025, 07/22/2025, and 09/29/2025 with gross proceeds of $148,799.00, $9,974.63, and $110,358.00 respectively. The filer certifies no undisclosed material adverse information.
Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics, reported a single non-derivative transaction on 09/22/2025. The Form 4 shows a sale of 688 shares of Abeona common stock at $5.43 per share, executed to cover tax obligations tied to the vesting of restricted stock awards. After the sale, Mr. O'Malley is reported to beneficially own 360,129 shares directly. The filing is submitted by one reporting person and is signed by Mr. O'Malley on 09/22/2025. The disclosure is limited to this transaction and its stated tax-related purpose.
Abeona Therapeutics (ABEO) Form 144 shows a proposed sale of 17,376 shares of common stock through Stifel Nicolaus & Company on 09/22/2025 with an aggregate market value of $101,749. The filing lists total shares outstanding of 51,156,736, so the proposed sale equals a small fraction of the outstanding float. The notice records an acquisition of 1,360 shares as Restricted Stock Units on 09/21/2025 with cash payment on 09/22/2025. It also discloses a sale by Brendan O'Malley of 17,428 shares on 07/09/2025 for gross proceeds of $102,053. The filer attests there is no undisclosed material adverse information.
Eric Crombez, a director of Abeona Therapeutics Inc. (ABEO), reported a sale of 4,718 shares of the company's common stock on 08/14/2025. The sale was executed to cover tax obligations arising from the vesting of restricted stock awards and was reported at a weighted average price of $6.9273, with individual trade prices ranging from $6.77 to $7.05. After the reported disposition, the reporting person beneficially owned 42,427 shares. The filing discloses the transaction code "S" indicating a sale and affirms that detailed per-trade price information can be provided on request.
Joseph Walter Vazzano, identified as the company's Chief Financial Officer, reported a sale of 15,000 shares of Abeona Therapeutics Inc. (ABEO) on 08/15/2025. The shares were sold at a weighted-average price of $7.3572, with transaction prices ranging from $7.20 to $7.48. After the sale, Vazzano beneficially owned 462,666 shares. The Form 4 was filed by a single reporting person and is signed by Vazzano on the transaction date.
Abeona Therapeutics (ABEO) Form 144: This notice shows an intended sale of 15,000 shares of common stock through Stifel Nicolaus with an aggregate market value of $110,358, scheduled approximately for 08/15/2025. The filer acquired 47,303 shares as restricted stock units on 06/05/2024 and indicates cash payment on 06/06/2025. Recent disclosed sales by the same person total 64,708 shares for gross proceeds of $278,087.63 across trades on 06/06/2025, 07/09/2025, and 07/22/2025.
The form is a routine Section 144 notice required for proposed sales by an affiliate and includes the filer’s representation that no undisclosed material adverse information is known. The shares to be sold represent a small fraction of the issuer’s reported 51,278,539 outstanding shares.
Abeona Therapeutics reported a materially different quarter driven by regulatory and one-time transaction events. The FDA approved ZEVASKYN on April 28, 2025, and the company recognized a $152.4 million gain from the sale of a Priority Review Voucher, producing net income of $108.8 million for the three months ended June 30, 2025 and $96.8 million for the six months ended June 30, 2025. Cash and cash equivalents rose to $163.5 million and short-term investments were $62.0 million, increasing total assets to $246.2 million and stockholders' equity to $163.6 million as of June 30, 2025.
Operationally the company remains a commercial-stage biopharmaceutical developer of cell and gene therapies: license revenues were modest ($0.4 million) and the six-month loss from operations before the PRV gain was $42.5 million. Debt principal under the Loan Agreement remains $20.0 million with current maturities of $5.6 million and a covenant to maintain $5.0 million in unrestricted cash. Warrant liabilities totaled $30.2 million. Management states available capital resources are sufficient to fund operations for at least the next 12 months.
Abeona Therapeutics, Inc. filed a Current Report on Form 8-K stating that on August 14, 2025 it issued a press release reporting its financial results for the quarter ended June 30, 2025. The press release is filed as Exhibit 99.1 to the report and a Cover Page Interactive Data File is included as Exhibit 104. The 8-K specifies that the press release and related information are incorporated as exhibits but are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference in other filings except by specific reference. The report is signed by CFO Joseph Vazzano.
A Schedule 13G/A reports that Suvretta Capital Management, LLC and Aaron Cowen each disclose beneficial ownership of 2,676,000 shares of Abeona Therapeutics common stock, representing 5.2% of the class, while Averill Master Fund, Ltd. holds 2,309,267 shares ( 4.5% ). Each reporting person shows zero sole voting or dispositive power and reports the corresponding amounts as shared voting and dispositive power. The filers state the securities are directly owned by advisory clients of Suvretta and that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
What is the current stock price of Abeona Therapeut (ABEO)?
What is the market cap of Abeona Therapeut (ABEO)?
